Clinical Trial Update: Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B [Phase 3]

View source ↗

Summary

Phase 3 trial of IB1001, a recombinant Factor IX product, for Hemophilia B has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• IB1001 (Recombinant Factor IX)

Snippet

Sponsor: Cangene Corporation | Conditions: Hemophilia B | Phase 3 | Status: WITHDRAWN